Alexion announces plans to initiate phase III Study of Ultomiris (ravulizumab-cwvz) in hospitalised patients with severe covid-19

Study will be conducted in a subset of ~270 adults with covid-19 who are hospitalised with severe pneumonia or acute respiratory distress syndrome and will evaluate the impact of treatment on survival, duration of mechanical ventilation, and hospital stay vs. best supportive care


Biospace Inc.